Carfostin is under clinical development by Asklepios BioPharmaceutical and currently in Phase II for Non-ischemic Cardiomyopathy. According to GlobalData, Phase II drugs for Non-ischemic Cardiomyopathy does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Carfostin LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Carfostin overview

Carfostin (BNP-CHF) is under development for the treatment of advanced stage III/IV chronic heart failure and chronic non-ischemic cardiomyopathy. The drug candidate is a protein and cellular therapy based recombinant adeno-associated virus (rAAV) biological nanoparticle. The drug candidate is based on Biological Nano Particles (BNP) technology and Self-Complementary Vector technology. It targets protein phosphatase 1.

Asklepios BioPharmaceutical overview

Asklepios BioPharmaceutical (AskBio) is AAV gene therapy development company that develops and markets novel protein and cellular based therapies. Its product pipeline includes therapies for the treatment of neuromuscular, central nervous system, heart related diseases including pompe, limb-girdle 2i, huntington’s, epilepsy, parkinson’s, and congestive heart failure (nanocor). AskBio has developed library of AAV biological nano particles that provides unsurpassed transduction. It serves pharmaceutical and biotechnology companies. AskBio is headquartered in Durham, North Carolina, the US.

For a complete picture of Carfostin’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.